Omnicell, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMCL research report →
Range $50 – $65
Price Chart
About the company
Omnicell, Inc. , together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process.
- CEO
- Randall A. Lipps
- IPO
- 2001
- Employees
- 3,450
- HQ
- Fort Worth, TX, US
Get TickerSpark's AI analysis on OMCL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.50B
- P/E
- 34.03
- Fwd P/E
- 13.09
- PEG
- 0.27
- P/S
- 1.23
- P/B
- 1.16
- EV/EBITDA
- 9.40
- Div Yield
- 0.00%
- Gross Margin
- 45.14%
- Op Margin
- 5.28%
- Net Margin
- 3.59%
- ROE
- 3.50%
- ROIC
- 2.74%
Latest fiscal year · YoY change
- Revenue
- $1.18B+6.5%
- Gross Profit
- $508.04M+7.9%
- Op Income
- $11.66M
- Net Income
- $2.05M-83.6%
- EPS
- $0.04-83.5%
- OCF Growth
- -32.2%
- FCF Growth
- -42.6%
- 52W High
- $55.00
- 52W Low
- $31.75
- 50D MA
- $35.12
- 200D MA
- $38.09
- Beta
- 0.89
- RSI (14)
- 36
- Avg Volume
- 562.69K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Omnicell delivered a better-than-expected third quarter, raised full-year profitability guidance, and said its next-generation Titan XT and OmniSphere pipeline continues to build even as customer decisions remain slow and back-end weighted.· October 29, 2026
- Q3 revenue was $308 million and non-GAAP EBITDA was $45 million, both above the high end of prior guidance.
- Non-GAAP EPS was $0.58; product revenue was about $173 million and service revenue was about $135 million.
- Full-year 2026 guidance was tightened and profitability raised: EBITDA to $187 million-$193 million and EPS to $2.48-$2.56.
- Management said Titan XT shipments are starting now, while OmniSphere is still targeting first-half 2027 general availability.
- Bookings remain back-end weighted; management said customer decision cycles are measured, especially for larger competitive deals.
Third-quarter 2026 total revenue was $308 million, above prior guidance of $301 million-$307 million. Non-GAAP EBITDA was $45 million, above prior guidance of $32 million-$37 million, and non-GAAP EPS was $0.58. Product revenue was approximately $173 million and service revenue was approximately $135 million. The company ended the quarter with $315 million in cash and cash equivalents and generated $20 million of free cash flow. For Q4, management guided to revenue of $295 million-$301 million, non-GAAP EBITDA of $30 million-$36 million, and non-GAAP EPS of $0.41-$0.49. Full-year 2026 guidance now calls for product bookings of $425 million-$560 million, revenue of $1.225 billion-$1.231 billion, product revenue of $684 million-$687 million, service revenue of $541 million-$544 million, year-end ARR of $660 million-$670 million, EBITDA of $187 million-$193 million, and EPS of $2.48-$2.56.
Randall Lipps framed the quarter as another strong execution period and tied the results to Omnicell’s strategy in autonomous medication management. He emphasized that health systems continue to view medication management as a priority, and said the company’s integrated hardware-plus-software offering is designed to reduce complexity and improve operational efficiency. His tone was constructive and confident, highlighting growing pipeline momentum, customer interest in cloud deployment, and the upcoming first Titan XT shipment as a major milestone.
Baird Radford focused on the company’s improved operating leverage and why profitability came in ahead of plan. He said Q3 EBITDA outperformance reflected cost efficiency, favorable product mix, favorable gross margins in both product and service, disciplined spending, and some expense timing shift into Q4. He also quantified several items: $315 million of cash, $20 million of free cash flow, about $6 million of incremental second-half memory costs, and a roughly $15 million Q2 tariff refund benefit that distorted margin comparisons. He raised full-year EBITDA and EPS guidance, while narrowing revenue and ARR ranges based on better visibility.
Analysts pressed management on why bookings guidance remains wide and back-end weighted, and whether any shortfall would simply roll into 2027. Management said the range reflects the binary nature of competitive deals, timing variability, and the early stage of the refresh cycle rather than any demand deterioration. Questions also focused on leasing, with management saying leases are becoming an important competitive tool and that about 30% of the marketplace is actively involved in leasing transactions. On OmniSphere, management said customers like the subscription model for its predictability, but pricing and durations are still being tested and no specific monetization numbers were shared.
The bull case from this call is that Omnicell is starting to convert a multi-year product refresh into real commercial traction. Management said the pipeline has grown since the prior call, customer conversations are getting deeper, Titan XT shipments are beginning, and OmniSphere is gaining interest as part of the broader enterprise solution. Higher EBITDA guidance, stronger-than-expected Q3 execution, and management’s repeated comments about operating leverage and eventual cloud-software economics support the optimistic view.
The main risk is timing: management repeatedly said bookings and revenue are back-end weighted, customer decisions are measured, and some large competitive deals may not convert until well into 2027. The company also flagged headwinds from memory costs, a modest ARR impact from 340B dynamics, and the fact that Titan XT is only just beginning to ship, so near-term monetization remains limited. In addition, Omnicell said OmniSphere pricing, duration, and economics are still being validated, so there is still execution and adoption uncertainty.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.6%
- Shares Outstanding
- 45.99M
- Float Shares
- 44.43M
of shares held by institutions
316 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for OMCL, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 7.72M | ▲ 176.18K |
| Vanguard Group Inc | 5.55M | ▼ 58.96K |
| Vanguard Portfolio Management LLC | 3.16M | ▲ 12.44K |
| Dimensional Fund Advisors LP | 2.56M | ▲ 106.07K |
| State Street Corp | 2.09M | ▲ 5.84K |
| Vanguard Capital Management LLC | 1.96M | ▼ 5.96K |
| Nomura Asset Management International Inc. | 1.46M | ▼ 142.21K |
| Bank Of America Corp | 1.31M | ▲ 405.41K |
| Nuveen, LLC | 1.31M | ▲ 276.86K |
| Geode Capital Management, LLC | 1.13M | ▼ 88.86K |
| Millennium Management LLC | 1.04M | ▼ 690.40K |
| Acadian Asset Management LLC | 1.01M | ▲ 292.61K |
Held by 456 ETFs
Biggest fund positions in OMCL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Radford Harlan Baird | other | 4,443 |
| Nov 15, 26 | NUTT BRIAN H. | other | 406 |
| Nov 15, 26 | Njoku Nnamdi | other | 3,670 |
| Nov 16, 26 | Njoku Nnamdi | sell | 3,083 |
| Nov 15, 26 | Manley Corey J | other | 4,025 |
| Nov 15, 26 | LIPPS RANDALL A | other | 12,349 |
| Aug 15, 26 | NUTT BRIAN H. | other | 937 |
| Aug 15, 26 | Njoku Nnamdi | other | 3,670 |
| Aug 17, 26 | Njoku Nnamdi | sell | 3,083 |
| Aug 15, 26 | LIPPS RANDALL A | other | 12,350 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OMCL coverage
Recent articles, reports, and earnings notes.
No research on OMCL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OMCL report →Omnicell: Turning A Net Cash Balance Sheet Into A Weapon Against Pyxis
seekingalpha.com · Nov 20
Here's Why Omnicell (OMCL) is a Strong Value Stock
zacks.com · Nov 19
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
zacks.com · Nov 19
Beat Value Traps: 4 Stocks With Attractive PEG Ratios to Buy Now
zacks.com · Nov 13
Buy These 3 Stocks with Broker Rating Upgrades for Big Gains
zacks.com · Nov 10
4 Undervalued Stocks That Could Benefit from a Wall Street Rally
zacks.com · Nov 10
Why Omnicell (OMCL) is a Top Momentum Stock for the Long-Term
zacks.com · Nov 9
Contrasting Coloplast A/S (OTCMKTS:CLPBY) & Omnicell (NASDAQ:OMCL)
defenseworld.net · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.